Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor.

Median OS of patients was 40.3 months in the PAN–BTZ–DEX arm compared to 35.8 months in the placebo group; this result did not reach statistical significance. 34 Of note, a higher percentage of patients in the placebo arm received post-study therapy, which may have confounded these OS results.

also in 111,027 other papers